(Reuters) – Merck said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it […]

While it is increasingly apparent that clonal hematopoiesis of indeterminate potential (CHIP) is associated with conditions that can dramatically affect an individual’s risk for both malignant […]

A new way of using artificial intelligence (AI) can predict breast cancer 5 years in advance with impressive accuracy — and unlike previous AI models, we […]

An advisory panel at the US Food and Drug Administration (FDA) lent support to bids that allow for earlier use of chimeric antigen receptor (CAR-T) therapies […]

For early-stage cervical cancer, non-radical surgery (simple hysterectomy or cone biopsy plus pelvic lymphadenectomy) appears safe with no lasting negative impact on quality of life, according […]

(Reuters) -Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial […]

Widely considered the father of cancer immunotherapy, Steven A. Rosenberg, MD, PhD, FAACR, has spent nearly 50 years analyzing the link between patients’ immune reaction and […]

TOPLINE: Secondary cancers were flagged in 4.3% of all adverse event reports among patients who received CAR T therapy, with T-cell malignancies comprising only 0.15% of […]

The US Food and Drug Administration has granted ponatinib (Iclusig, Takeda) accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic […]